Discriminative power to distinguish between patients in high and low disease activity
| Patients starting bDMARD treatment | Patients not starting or changing s/bDMARD treatment for ≥60 days | Standardised mean difference* | |
| Number of visits/patients | 391/290 | 1946/774 | |
| DAPSA, mean (SD)/median (25th, 75th percentile) | 29.1 (17.4)/26.1 (18.0, 37.5) | 15.1 (13.7)/12.1 (5.1, 20.4) | 0.90 |
| DAPSA28, mean (SD)/median (25th, 75th percentile) | 26.9 (15.7)/24.5 (16.1, 34.4) | 13.8 (12.5)/10.9 (4.6, 18.7) | 0.93 |
*Standardised mean difference=mean of DAPSA or DAPSA28 in patients starting bDMARD subtracted by the mean of DAPSA or DAPSA28 in patients not starting or changing s/bDMARD) divided by pooled SD of both treatment groups.
DAPSA, Disease Activity index for PSoriatic Arthritis; DMARD, disease-modifying anti-rheumatic drug;bDMARD, biological DMARD; s/bDMARD, synthetic/biological DMARD.